Sigyn Therapeutics enters share surrender agreement with CTO to cancel 2.56M shares

Sigyn Therapeutics, Inc.

Craig Roberts, CTO and board member, surrenders 2,564,000 shares of common stock for cancellation.
Shares are cancelled and not held as treasury shares; no further claims against the company.
As of Jan 9, 2024, total outstanding shares are 48,972,602 following this surrender and note conversions.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Sigyn Therapeutics, Inc. entered into Share Surrender Agreement with Craig Roberts (effective 2024-01-09).

Action: entry
Counterparty: Craig Roberts
Effective: 2024-01-09

Exact text from the filing

On January 9, 2024, Sigyn Therapeutics, Inc. (the “Company”) entered into a Share Surrender Agreement with Craig Roberts, Chief Technical Officer and member of the board of directors of the Company (the “Shareholder”), whereas the parties agreed that 2,564,000 shares of common stock, par value $0.001, shall be surrendered by the Shareholder to the Company for cancellation and shall subsequently not be held as treasury shares or represent any claim against the Company whatsoever, effective immediately.

View on SEC.gov

Browse all material agreements →

Sigyn Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-002048

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.